Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the September 19. 2013 edition of the journal Cell Reports, a team of researchers based at The Wistar Institutein Philadelphia, PA (USA), report on the mechanics by which melanoma can evolve resistance to a powerful combination of drugs ? BRAF and MEK inhibitors.
The researchers found that resistant melanomas acquired a mutation in the MEK2 gene and multiple copies of the mutant BRAF oncogene, simultaneously decreasing the sensitivity to both drug targets. Their findings also uncovered a new potential target for melanoma therapy, a protein called S6K. Furthermore, early studies in a laboratory model for melanoma show that a triple combination of drug inhibitors halted the growth of resistant tumors.
A deadly disease
Melanoma is a form of cancer that begins in melanocytes, the cells that make the pigment melanin. It may begin in a mole on the skin, but can also begin in other pigmented tissues, such as in the eye or in the intestines. Melanoma is also the deadliest, most aggressive form of skin cancer. While surgical treatment of early-stage melanoma leads to 90% cure rates, advanced melanoma is notoriously resistant to chemotherapy and has a tendency to metastasize, or spread, throughout the body.
World Health Organization, cases of the disease continue to rise internationally. Additionally, estimates from the U.S. National Cancer Institute suggest that there will be more than 76,000 new cases and over 9,400 deaths from melanoma in the United States in 2013. The observed increase in melanoma cases has has helped spur research into therapies such as BRAF and MEK inhibitors.
…now we have a mechanism and a rational approach to develop new drugs and more effective combinations aimed at solving drug resistance in melanoma…
Developing new drugs
“Melanoma tumors are particularly adept at rewiring themselves so that anticancer drugs lose their effectiveness, and we must continue to outthink the disease in order to block off all points at which it can evade therapy,” said Jessie Villanueva, Ph.D., assistant professor in Wistar’s NCI-designated Cancer Center and member of The Wistar Institute Melanoma Research Center. “There are currently therapeutics available that can block the pathway that leads to S6K, but we are also interested in developing inhibitors to S6K itself.”
BRAF inhibitors were developed in response to discoveries that a specific mutation in the BRAF gene was responsible for nearly 50% of melanoma cases. The BRAF protein is part of the MAP kinase pathway, a chain of enzymatic reactions?including the enzyme MEK?that is commonly over-activated in cancers.
“Combining BRAF and MEK inhibitors was conceived as a one-two punch against the MAP kinase pathway,” Villanueva said, “and while it is considered successful in the clinic, some tumors do not respond and others develop resistance, underscoring the need for new therapeutic strategies.”
As cancer clinicians began to see patients develop resistance to BRAF and MEK inhibitors, the scientist at The Wistar Institutebegan to explore the mechanisms by which tumors develop resistance. They found that melanoma cells used different tactics for each enzyme. Mutations in MEK2, for example, would render anti-MEK therapies ineffective. To defeat BRAF inhibitors, surviving melanoma cells exhibited numerous copies of the mutant BRAF gene, enough to overpower anti-BRAF drugs.
“There were simply too many copies of BRAF to block, it became a numbers game and the mutation was winning,” Villanueva said. “Increasing the dosage of BRAF inhibitors could be one solution, but that cannot be done in patients without causing serious toxic effects.”
A possible answer, the scientists reasoned, was in the PI3K/mTOR pathway, a network of signaling enzymes often active within melanoma cells. However, they could find no sign that any of the usual suspects? points along the pathway commonly known to be involved in cancers?had any evident part in BRAF/MEK resistance. It was not until they examined farther “downstream” that they found persistent activation of S6K, an enzyme that appears to be at the point where P13K/mTOR and MAP kinase pathways merge.
Because there are currently no effective S6K inhibitors, researchers tried combinations of inhibitors against BRAF, MEK and PI3K/mTOR in a mouse model of melanoma. A triple combination of dabrafenib (Tafinlar?, GSK), trametinib (Mekinist?, GSK), and the PI3K/mTOR inhibitor GSK2126458, a highly potent inhibitor of PI3K and the mammalian Target of Rapamycin (mTOR), led to sustained tumor growth inhibition in vivo. “With a triple combination of drugs, the tumors slow down and just stop growing,” Villanueva explained.
Although a cocktail of two drugs, a combination of BRAF and PI3K/mTOR inhibitors, for example, might work, the researchers postulated that using three drugs could be more potent and counter intuitively less toxic at the same time. “We followed these mice with melanoma for three weeks, tumors remain stable, and mice did not show any evident signs of toxicity, ” Villanueva noted.
“For patients, it is not a simple matter of introducing triple combination therapies into use,” Villanueva said, ” but now we have a mechanism and a rational approach to develop both new drugs and more effective combinations aimed at solving drug resistance in melanoma. Our findings might also offer important lessons for other forms of metastatic cancer.”
Unrelated to this research,the U.S. Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of dabrafenib and trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.The applications are based on data from a randomised Phase I/II study comparing combination therapy with dabrafenib and trametinib to dabrafenib monotherapy in adult patients with BRAF V600E and V600K mutation positive metastatic melanoma.Use of dabrafenib and trametinib in combination is investigational and not approved anywhere in the world.
For more information:
 Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen H, Li B, Swoboda RK, et al. Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma Cell Reports, 19 September 2013 [Article]
 Highlights of Prescribing Information: trametinib (Mekinist) [PI-PIL 2013]
 Highlights of Prescribing Information: dabrafenib (Tafinlar) [PI 2013]
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley
Communication around the world.